{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-038522","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.890761+00:00","generated_at":"2026-06-06T00:08:02.906554+00:00","sec_items":["1.01","2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"KalVista prices $160.1M public offering of common stock and pre-funded warrants","bullets":["Offering includes 7,016,312 shares at $15.25 and pre-funded warrants for 3,483,688 shares; gross proceeds $160.1M.","Net proceeds estimated at ~$150.1M to fund sebetralstat development and oral Factor XIIa program.","Cash, cash equivalents and marketable securities approximately $76M as of Jan 31, 2024 (preliminary).","Underwriters granted 30-day option to purchase up to 1,575,000 additional shares at same price.","Closing expected Feb 20, 2024; Jefferies, Leerink, Stifel, Cantor joint book-runners."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-038522","json":"https://secwatch.observer/filing/0001193125-24-038522.json","markdown":"https://secwatch.observer/filing/0001193125-24-038522.md","text":"https://secwatch.observer/filing/0001193125-24-038522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312524038522/0001193125-24-038522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312524038522/d729040d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:08:02.906554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4e46287c2026da065ecfbaa8771f332c8242df6","claim":"KalVista Pharmaceuticals, Inc. entered into Underwriting Agreement with Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co. valued at approximately $150.1 million (effective 2024-02-14).","evidence_excerpt":"On February 14, 2024, KalVista Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co., as the representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell (i) an aggregate of 7,016,312 shares of its common stock (the “Shares”) and (ii) pre-funded warrants to purchase 3,483,688 shares of the Company’s common stock in lieu of its common stock (the “Pre-Funded Warrants”) to certain investors, to the Underwriters (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000119312524038522/0001193125-24-038522-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co."},{"label":"Value","value":"approximately $150.1 million"},{"label":"Effective","value":"2024-02-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}